These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19451321)

  • 1. Safety evaluation of 1% tenofovir gel in healthy men.
    Schwartz JL; Poindexter A; Wheeless A; Mauck CK; Callahan MM
    Int J STD AIDS; 2009 Jun; 20(6):384-6. PubMed ID: 19451321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Male tolerance of ACIDFORM gel.
    Schwartz JL; Poindexter A; Schmitz SW; Mauck C; Callahan MM
    Contraception; 2005 Jun; 71(6):443-6. PubMed ID: 15914134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety trial of the vaginal microbicide cellulose sulfate gel in HIV-positive men.
    Jespers V; Buvé A; Van Damme L
    Sex Transm Dis; 2007 Jul; 34(7):519-22. PubMed ID: 17297382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
    Mayer KH; Maslankowski LA; Gai F; El-Sadr WM; Justman J; Kwiecien A; Mâsse B; Eshleman SH; Hendrix C; Morrow K; Rooney JF; Soto-Torres L;
    AIDS; 2006 Feb; 20(4):543-51. PubMed ID: 16470118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a safety and feasibility study of the diaphragm used with ACIDFORM Gel or K-Y Jelly.
    von Mollendorf CE; Van Damme L; Moyes JA; Rees VH; Callahan MM; Mauck CK; Puren AJ; Tweedy K; Taylor D
    Contraception; 2010 Mar; 81(3):232-9. PubMed ID: 20159180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial comment: tenofovir-related nephrotoxicity--who's at risk?
    Gupta Samir K
    AIDS Read; 2007 Feb; 17(2):102-3. PubMed ID: 17323509
    [No Abstract]   [Full Text] [Related]  

  • 7. Renal toxicity associated with tenofovir use.
    Rodriguez-Nóvoa S; Alvarez E; Labarga P; Soriano V
    Expert Opin Drug Saf; 2010 Jul; 9(4):545-59. PubMed ID: 20384533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial comment: mixing tenofovir with other nephrotoxins--how safe is this?
    Gupta SK
    AIDS Read; 2009; 19(6):246. PubMed ID: 19642244
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women.
    El-Sadr WM; Mayer KH; Maslankowski L; Hoesley C; Justman J; Gai F; Mauck C; Absalon J; Morrow K; Mâsse B; Soto-Torres L; Kwiecien A
    AIDS; 2006 May; 20(8):1109-16. PubMed ID: 16691061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trials planned to confirm efficacy of tenofovir microbicide gel.
    McEnery R
    IAVI Rep; 2010; 14(5):18. PubMed ID: 21158227
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment--case report and review of literature.
    Malik A; Abraham P; Malik N
    J Infect; 2005 Aug; 51(2):E61-5. PubMed ID: 16038754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal safety of tenofovir disoproxil fumarate.
    Sax PE; Gallant JE; Klotman PE
    AIDS Read; 2007 Feb; 17(2):90-2, 99-104, C3. PubMed ID: 17323508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.
    Psevdos G; Gonzalez E; Sharp V
    AIDS Read; 2009; 19(6):245-8. PubMed ID: 19642243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.
    Lowe SH; van Leeuwen E; Droste JA; van der Veen F; Reiss P; Lange JM; Burger DM; Repping S; Prins JM
    Ther Drug Monit; 2007 Oct; 29(5):566-70. PubMed ID: 17898645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women.
    Nel AM; Coplan P; van de Wijgert JH; Kapiga SH; von Mollendorf C; Geubbels E; Vyankandondera J; Rees HV; Masenga G; Kiwelu I; Moyes J; Smythe SC
    AIDS; 2009 Jul; 23(12):1531-8. PubMed ID: 19550287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, comparative safety study of a prefilled plastic and user-filled paper applicator with candidate microbicide tenofovir 1% gel.
    Cohen JA; Brache V; Foster J; Cochon L; Callahan M; Schwartz J
    Sex Transm Dis; 2013 Jun; 40(6):476-81. PubMed ID: 23677021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial comment: tenofovir nephrotoxicity--the disconnect between clinical trials and real-world practice.
    Atta MG; Fine DM
    AIDS Read; 2009 Mar; 19(3):118-9. PubMed ID: 19334329
    [No Abstract]   [Full Text] [Related]  

  • 18. Male tolerance study of 1% C31G.
    Mauck CK; Frezieres RG; Walsh TL; Schmitz SW; Callahan MM; Bax R
    Contraception; 2004 Sep; 70(3):221-5. PubMed ID: 15325891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor.
    Schwartz JL; Kovalevsky G; Lai JJ; Ballagh SA; McCormick T; Douville K; Mauck CK; Callahan MM
    Sex Transm Dis; 2008 Apr; 35(4):414-9. PubMed ID: 18362865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases.
    Irizarry-Alvarado JM; Dwyer JP; Brumble LM; Alvarez S; Mendez JC
    AIDS Read; 2009 Mar; 19(3):114-21. PubMed ID: 19334328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.